1. Tenofovir (Viread), first novel antiviral agent in six years, approved by FDA. Treatment Action Group website. 2001 [cited 2019 March 25]. Available from: http://www.treatmentactiongroup.org/tagline/2001/november/tenofovir-viread-first-novel-antiviral-agent-six-years-approved-fda.
2. Rationale for tenofovir as the first choice in the first-line treatment of HIV. Medicins sans Frontieres Access Campaign website. 2012 [cited 2019 March 25]. Available from: https://msfaccess.org/rationale-tenofovir-first-choice-first-line-treatment-hiv.
3. Gilead’s tenofovir access program for developing countries. Doctors Without Borders website. 2006 [cited 2019 March 25]. Available from: https://www.doctorswithoutborders.org/what-we-do/news-stories/research/gileads-tenofovir-access-program-developing-countries.
4. Access to AIDS medicines stumbles on trade rules;J Wise;Bull WHO,2006
5. Speeding access to vaccines and medicines in low- and middle-income countries: A case for change and a framework for optimized product market authorization;V Ahonkhai;PLoS ONE,2016